来源：新浪证券-红岸工作室 11月21日，海泰新光跌2.14%，成交额4300.69万元，换手率0.79%，总市值54.17亿元。 异动分析 主力持仓 主力没有控盘，筹码分布非常分散，主力成交额2002.54万，占总成交额的9.01%。 医疗器械概念+人民币贬值受益+专精特新 1、公司始终致力于将光学技术与医疗器械行业的前沿应用趋势相结合，研究发展高性能的尖端内窥镜 器械产品。目前，公司是国内少有的具备从核心部件、关键设备到系统集成的行业垂直整合能力的企 业。 2、根据2024年年报，公司海外营收占比为69.12%，受益于人民币贬值。 3、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部专精特新 小巨人企业名单。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入-460.60万，占比0.11%，行业排名62/132，连续3日被主力资金减仓； ...

来源：新浪证券-红岸工作室 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入-459.02万，占比0.12%，行业排名84/132，连续3日被主力资金减仓；所属行业主力净流 入-11.41亿，连续3日被主力资金减仓。 区间今日近3日近5日近10日近20日主力净流入-459.02万-1002.64万-1083.34万-721.59万-5530.67万 11月20日，海泰新光跌1.97%，成交额3710.52万元，换手率0.66%，总市值55.36亿元。 异动分析 医疗器械概念+人民币贬值受益+专精特新 1、公司始终致力于将光学技术与医疗器械行业的前沿应用趋势相结合，研究发展高性能的尖端内窥镜 器械产品。目前，公司是国内少有的具备从核心部件、关键设备到系统集成的行业垂直整合能力的企 业。 2、根据2024年年报，公司海外营收占比为69.12%，受益于人民币贬值。 3、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞 ...

来源：新浪证券-红岸工作室 11月13日，海泰新光涨1.59%，成交额4532.93万元，换手率0.78%，总市值58.82亿元。 异动分析 医疗器械概念+专精特新+人民币贬值受益 1、公司始终致力于将光学技术与医疗器械行业的前沿应用趋势相结合，研究发展高性能的尖端内窥镜 器械产品。目前，公司是国内少有的具备从核心部件、关键设备到系统集成的行业垂直整合能力的企 业。 2、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部专精特新 小巨人企业名单。 3、根据2024年年报，公司海外营收占比为69.12%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 截至9月30日，海泰新光股东户数5188.00，较上期减少1.84%；人均流通股23106股，较上期增加 1.87%。2025年1月-9月，海泰新光实现营业收入4.48亿元，同比增长40.4 ...

Core Viewpoint - The company, Qindao Haitai New Light Technology Co., Ltd., is focused on integrating optical technology with cutting-edge applications in the medical device industry, particularly in high-performance endoscope products, and has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise in China [2][7]. Group 1: Company Overview - Qindao Haitai New Light was established on June 11, 2003, and went public on February 26, 2021. The company specializes in the research, development, production, and sales of medical endoscope devices and optical products [7]. - The revenue composition of the company includes 64.86% from medical endoscope devices, 21.63% from optical products, 13.09% from maintenance services, and 0.42% from leasing [7]. - As of September 30, 2025, the company reported a revenue of 448 million yuan, representing a year-on-year growth of 40.47%, and a net profit attributable to shareholders of 136 million yuan, also showing a growth of 40.03% year-on-year [7]. Group 2: Market Position and Financials - The company has a significant overseas revenue share of 69.12%, benefiting from the depreciation of the Chinese yuan [3]. - The company has distributed a total of 277 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [8]. - As of September 30, 2025, the number of shareholders decreased by 1.84% to 5,188, while the average circulating shares per person increased by 1.87% to 23,106 shares [7]. Group 3: Stock Performance and Technical Analysis - On November 12, the stock price of Haitai New Light fell by 0.10%, with a trading volume of 34.05 million yuan and a turnover rate of 0.59%, resulting in a total market capitalization of 5.79 billion yuan [1]. - The average trading cost of the stock is 46.51 yuan, with recent chip reduction slowing down. The current stock price is near a support level of 47.14 yuan, indicating potential for a rebound if it holds above this level [6].

Core Viewpoint - The company, Qindao Haitai New Light Technology Co., Ltd., is focused on integrating optical technology with cutting-edge applications in the medical device industry, particularly in high-performance endoscope products. It has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, indicating its strong market position and technological capabilities [2][7]. Company Overview - Qindao Haitai New Light was established on June 11, 2003, and went public on February 26, 2021. Its main business includes the research, development, production, and sales of medical endoscope devices and optical products. The revenue composition is as follows: medical endoscope devices 64.86%, optical products 21.63%, maintenance services 13.09%, and leasing 0.42% [7]. - As of September 30, 2025, the company reported a revenue of 448 million yuan, representing a year-on-year growth of 40.47%, and a net profit attributable to shareholders of 136 million yuan, also showing a growth of 40.03% [7]. Market Position and Financials - The company has a significant overseas revenue share of 69.12%, benefiting from the depreciation of the Renminbi [3]. - The total market capitalization of the company is 5.828 billion yuan, with a trading volume of 38.349 million yuan and a turnover rate of 0.66% on November 7 [1]. Shareholder Information - As of September 30, 2025, the number of shareholders is 5,188, a decrease of 1.84% from the previous period. The average circulating shares per person increased by 1.87% to 23,106 shares [7]. - The company has distributed a total of 277 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [8]. Technical Analysis - The average trading cost of the stock is 46.47 yuan, with the current price approaching a support level of 48.40 yuan. A breach of this support level may indicate a potential downward trend [6].

Core Viewpoint - The company, Qindao Haitai New Light Technology Co., Ltd., is focused on integrating optical technology with cutting-edge applications in the medical device industry, particularly in high-performance endoscopic instruments. It has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which enhances its competitiveness and stability in the industry [2][3]. Company Overview - Qindao Haitai New Light was established on June 11, 2003, and went public on February 26, 2021. Its main business includes the research, development, production, and sales of medical endoscopic instruments and optical products. The revenue composition is as follows: medical endoscopic instruments 64.86%, optical products 21.63%, maintenance services 13.09%, and leasing 0.42% [7]. - As of September 30, 2025, the company reported a revenue of 448 million yuan, a year-on-year increase of 40.47%, and a net profit attributable to shareholders of 136 million yuan, also up 40.03% year-on-year [7]. Market Position and Financials - The company has a significant overseas revenue share of 69.12%, benefiting from the depreciation of the RMB [3]. - The total market capitalization is 5.868 billion yuan, with a trading volume of 42.7961 million yuan and a turnover rate of 0.73% on November 6 [1]. - The average trading cost of the stock is 46.52 yuan, with the current price near a support level of 48.40 yuan [6]. Shareholder Information - As of September 30, 2025, the number of shareholders is 5,188, a decrease of 1.84% from the previous period. The average number of circulating shares per person is 23,106, an increase of 1.87% [7]. - The company has distributed a total of 277 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [8].

Core Viewpoint - The company, Qindao Haitai New Light Technology Co., Ltd., is focused on integrating optical technology with cutting-edge applications in the medical device industry, particularly in high-performance endoscopic instruments. It has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, indicating its strong market position and technological capabilities [2][7]. Company Overview - Qindao Haitai New Light was established on June 11, 2003, and went public on February 26, 2021. Its main business includes the research, development, production, and sales of medical endoscopic instruments and optical products. The revenue composition is as follows: medical endoscopic instruments 64.86%, optical products 21.63%, maintenance services 13.09%, and leasing 0.42% [7]. - As of September 30, 2025, the company reported a revenue of 448 million yuan, representing a year-on-year growth of 40.47%, and a net profit attributable to shareholders of 136 million yuan, also showing a growth of 40.03% [7]. Market Position and Financials - The company has a significant overseas revenue share of 69.12%, benefiting from the depreciation of the Renminbi [3]. - The total market capitalization of the company is 5.881 billion yuan, with a trading volume of 43.31 million yuan and a turnover rate of 0.74% on November 5 [1]. Shareholder and Institutional Holdings - As of September 30, 2025, the number of shareholders is 5,188, a decrease of 1.84% from the previous period. The average circulating shares per person increased by 1.87% to 23,106 shares [7]. - The company has distributed a total of 277 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [8]. Technical Analysis - The average trading cost of the stock is 46.49 yuan, with recent reductions in holdings but at a slowing pace. The current stock price is near a support level of 48.40 yuan, which is critical for potential rebounds [6].

信澳中小盘混合A（610004）基金经理为曾国富、李点典。 截至发稿，曾国富累计任职时间17年91天，现任基金资产总规模4.81亿元，任职期间最佳基金回报 109.1%， 任职期间最差基金回报-57.43%。 李点典累计任职时间1年10天，现任基金资产总规模5.7亿元，任职期间最佳基金回报37.57%， 任职期 间最差基金回报15.71%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 10月24日，海泰新光跌5.25%，截至发稿，报48.40元/股，成交1.60亿元，换手率2.67%，总市值58.02亿 元。海泰新光股价已经连续5天下跌，区间累计跌幅6.7%。 资料显示，青岛海泰新光科技股份有限公司位于山东省青岛市崂山区科苑纬四路100号，成立日期2003 年6月11日，上市日期2021年2月26日，公司主营业务涉及医用内窥镜器械和光学产品的研发、生产和销 售。主营业务收入构成为：医用内窥镜器械64.86%，光学产品21.63%，维修服务13.09%，租赁0.42%。 ...

Core Viewpoint - The company's medical endoscope equipment business is expected to be impacted by US-China tariffs, while the maintenance services and optical products business are performing well. Looking ahead to the second half of the year, strong demand from US clients is anticipated, with overseas shipment volumes expected to continue growing due to accelerated order deliveries. Revenue in Q3 2025 is projected to grow rapidly on a low year-on-year basis, with profit growth expected to outpace revenue growth. The collaboration with US clients is likely to deepen, with ongoing development of new endoscope types and next-generation systems, alongside rapid growth in maintenance services and steady progress in new projects like the gas insufflator, which will contribute to long-term growth and performance increments [1]. Financial Performance - In the first half of 2025, the company achieved operating revenue, net profit attributable to shareholders, and net profit excluding non-recurring items of 266 million yuan, 74 million yuan, and 72 million yuan, respectively, representing year-on-year growth of 20.50%, 5.52%, and 12.07%. Basic earnings per share were 0.62 yuan per share [2]. Business Segment Analysis - In the first half of 2025, the medical endoscope equipment revenue was 172 million yuan (+11.70%), accounting for 64.86% of total revenue, with growth pressured by US tariffs. Optical products revenue was 57 million yuan (+34.62%), making up 21.63% of total revenue, with medical optical products growing by 48% due to significant increases in diagnostic analysis and oral scanning products. Maintenance services revenue reached 35 million yuan (+60.58%), driven by the continuous increase in market share of the company's products. The maintenance business's gross margin was 84%, significantly higher than other segments, indicating potential positive contributions to overall gross margin [4]. Outlook for the Second Half - The company has effectively reduced tariff impact through proactive overseas capacity layout, with most products shipped to the US now being produced and delivered from the Thailand factory. Strong demand from US clients is expected to continue, with accelerated order deliveries likely to boost overseas shipment volumes. The collaboration with US clients is deepening, with the development of next-generation endoscope systems incorporating the company's optical defogging patent technology. The company is also exploring collaborations on gas insufflators and 3D endoscope systems, with the gas insufflator project progressing rapidly towards customer testing and subsequent FDA registration [5]. Profitability and Cash Flow - The company's gross margin for the first half of 2025 was 65.84% (+1.75 percentage points), showing slight growth. The sales expense ratio was 7.48% (+2.83 percentage points), reflecting increased spending on market expansion and marketing network improvement. The management expense ratio remained stable at 10.80% (-0.11 percentage points), while the R&D expense ratio improved to 12.51% (-1.47 percentage points) due to revenue growth. The operating cash flow net amount was 81 million yuan, up 25.87% year-on-year, driven by increased sales and improved cash collection efficiency [7][6]. Long-term Growth Potential - The company is a leading upstream manufacturer of fluorescent rigid endoscopes in China. In the short to medium term, strong demand from US clients and successful production transitions at the Thailand factory are expected to support steady growth in ODM business. The ongoing deepening of collaboration with US clients, alongside rapid growth in maintenance services and new projects, will lay a foundation for long-term growth and performance increments. The company's optical technology advantages and strong vertical integration capabilities position it well for future growth through the expansion of new clients and application areas [8].

Core Viewpoint - The company, Haitai New Light, has shown a significant increase in stock price and trading volume, indicating positive market sentiment and potential growth opportunities in the medical device sector, particularly in optical technology applications [1][2]. Company Overview - Haitai New Light Technology Co., Ltd. is located in Qingdao, Shandong Province, and was established on June 11, 2003. The company went public on February 26, 2021, and specializes in the research, development, production, and sales of medical endoscope devices and optical products [7]. - The company's main business revenue composition includes: medical endoscope devices (64.86%), optical products (21.63%), maintenance services (13.09%), and leasing (0.42%) [7]. Financial Performance - For the first half of 2025, the company achieved a revenue of 266 million yuan, representing a year-on-year growth of 20.50%. The net profit attributable to the parent company was 74.44 million yuan, with a year-on-year increase of 5.52% [7]. - As of June 30, 2025, the company has distributed a total of 277 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [8]. Market Position and Recognition - The company is recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title awarded to small and medium-sized enterprises in China that excel in niche markets and possess strong innovation capabilities [2]. - Haitai New Light has a vertical integration capability in the industry, covering core components, key equipment, and system integration, making it one of the few companies in China with such comprehensive capabilities [2]. International Revenue Impact - The company's overseas revenue accounted for 69.12% of total revenue in the 2024 annual report, benefiting from the depreciation of the Chinese yuan [3].